Industry is showing a very high level of readiness for upcoming new packaging and labelling measures impacting the UK market, according to the Medicines and Healthcare products Regulatory Agency (MHRA).
The UK regulator has issued a final reminder to remaining marketing authorization holders to ensure they are prepared for the changes ahead of the deadline of December 31.
The vast majority of companies - nearly 90% - have already submitted updated artwork to ensure compliance with the new arrangements for medicines following the Windsor Framework, a post-Brexit legal agreement between the European Union (EU) and the UK which adjusts the operation of the Northern Ireland Protocol.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze